Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CMC1 pseudogene 1 (abbreviated CMC1P1) is a pseudogene, which means it is a genomic DNA sequence similar to a functional gene but generally considered non-coding and non-functional due to disabling mutations. Pseudogenes do not encode functional proteins and are not recognized as direct targets for drug development or therapy. While some pseudogenes have recently been implicated in gene expression regulation and disease association through RNA-based regulatory mechanisms (such as competing for microRNAs), there is no publicly available evidence indicating that CMC1P1 has such functions[2][3][4][5]. Additional context: Pseudogenes are typically classified into three molecular types: unitary, unprocessed (duplicated), and processed pseudogenes (retrotransposed)[4]. They are, in general, considered biologically inert, though a minority can impact gene regulation through RNA-level interactions in some contexts[3][4]. However, such roles must be established individually; no such function has been reported for CMC1P1. If your interest is in a functional molecule or target, a different name or identifier may be needed, as CMC1P1 does not correspond to an established target class.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CMC1 pseudogene 1 (CMC1P1).